Extracellular vesicles – A promising avenue for the detection and treatment of infectious diseases?

[Display omitted] Extracellular vesicles (EVs) have gained increasing attention as novel disease biomarkers and as promising therapeutic agents. These cell-derived, phospholipid-based particles are present in many – if not all – physiological fluids. They have been shown to govern several physiologi...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmaceutics and biopharmaceutics 2017-09, Vol.118, p.56-61
Main Authors: Fuhrmann, Gregor, Neuer, Anna Lena, Herrmann, Inge K.
Format: Article
Language:English
Subjects:
Antibiotic resistance
Bacteria - immunology
Bacteria - metabolism
Bacterial Physiological Phenomena
Biofilms
Biosensing
Cell Communication - physiology
Communicable Diseases - diagnosis
Communicable Diseases - microbiology
Communicable Diseases - therapy
Drug therapy
Exosomes
Exosomes - immunology
Exosomes - metabolism
Humans
Immune response
Vaccines - immunology
Vaccines - metabolism
Vaccines - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Extracellular vesicles (EVs) have gained increasing attention as novel disease biomarkers and as promising therapeutic agents. These cell-derived, phospholipid-based particles are present in many – if not all – physiological fluids. They have been shown to govern several physiological processes, such as cell-cell communication, but also to be involved in pathological conditions, for example tumour progression. In infectious diseases, EVs have been shown to induce host immune responses and to mediate transfer of virulence or resistance factors. Here, we discuss recent developments in using EVs as diagnostic tools for infectious diseases, the development of EV-based vaccines and the use of EVs as potential anti-infective entity. We illustrate how EV-based strategies could open a viable new avenue to tackle current challenges in the field of infections, including barrier penetration and growing resistance to antimicrobials.
ISSN:0939-6411
1873-3441
DOI:10.1016/j.ejpb.2017.04.005